

1. B. Aronsson, P. Bárány, C-E. Nord, B. Nyström, P. Stenvinkel. Clostridium difficile-associated diarrhoea in uremic patients. *Eur J Clin Microbiol.* 1987; 6: 352-6.
2. P. Stenvinkel, A. Alvestrand. Loop diuretic-induced pancreatitis with rechallenge in a patient with malignant hypertension and renal insufficiency. *Acta Med Scand* 1988; 224: 89-91.
3. P. Stenvinkel, A. Alvestrand, J. Bergström. Factors influencing progression of renal failure. *J Int Med.* 1989; 226: 183-88.
4. P. Stenvinkel, P. Bárány, I. Björkhem, K. Einarsson. Decreased concentrations of deoxycholic acid in serum of uremic patients with diarrhoea. *Scand J Clin Lab Invest.* 1990; 50: 337-416.
5. P. Stenvinkel, L. Hjelte, G. Alvan, A. Hedman, E. Hultman, B. Strandvik. Decreased renal clearance of sodium in cystic fibrosis. *Acta Paediatr Scand.* 1991; 80: 194-198.
6. P. Stenvinkel, A.K. Sagggar Malik, H. Wahrenberg, U. Diczfalusy, J. Bolinder, A. Alvestrand. Impaired intrarenal dopamine production following intravenous sodium chloride infusion in insulin-dependent (type-1) diabetes mellitus. *Diabetologia* 1991; 34: 114-118.
7. P. Bárány, P. Stenvinkel, C-E. Nord, J. Bergström. Clostridium difficile infection - a poor prognostic sign in uremic patients? *Clin Nephrology.* 1992; 38: 53-57.
8. P. Stenvinkel, A.K. Sagggar-Malik, A. Alvestrand. Renal hemodynamics and tubular sodium handling following volume expansion with sodium chloride (NaCl) and glucose in healthy man. *Scand J Clin Lab Invest.* 1992; 52: 837-846.
9. P. Stenvinkel, J. Bolinder, A. Alvestrand. Effects of insulin on renal hemodynamics and the proximal and distal tubular sodium handling in healthy subjects. *Diabetologia* 1992; 35: 1042-1048.
10. G. Cederblad, P. Stenvinkel, U. Widstam-Attorps. Nya och gamla metoder att mäta njurfunktioner. Effektivare behandling kräver bättre undersökningar. *Läkartidningen* 1993; 44: 3853-60.
11. P. Stenvinkel, L. Berglund, O. Heimbürger, E. Pettersson, A. Alvestrand. Lipoprotein(a) in nephrotic syndrome. *Kidney Int* 1993; 44: 1116-1123.
12. P. Stenvinkel, A. Alvestrand. Insulin causes renal vasodilation independently of renal prostaglandins in healthy humans. *Nephrol Dial Transplant.* 1994; 9: 1728-1733.
13. P. Stenvinkel, A. Ottosson-Seeberger, A. Alvestrand. Renal haemodynamics and sodium handling in moderate renal insufficiency: The role of insulin resistance and dyslipidemia. *J Am Soc Nephrol.* 1995; 5: 1-10.
14. P. Stenvinkel. Low molecular weight heparin - does it favourably affect lipid levels? *Nephrol Dial Transpl* 1995; 10: 16-18

15. P. Stenvinkel. Sodium and insulin - is there a relationship? *Nephrol Dial Transplant.* 1995;10:1286-7.
16. P. Stenvinkel. Akut njursvikt kan förebyggas. Nya rön om betydelsen av hypoxi i njurmärgen. *Läkartidningen* 1995; 40: 3667-3669.
17. P. Stenvinkel, A. Ottosson-Seeberger, J. Bolinder, A. Alvestrand. Effect of insulin on renal sodium handling and renal hemodynamics in insulin dependent (Type-1) diabetes mellitus. *Acta Diabetologica* 1995, 32: 230-234.
18. P. Stenvinkel, L. Berglund. Lipoprotein(a) in chronic renal disease. *Mineral Electrolyt Metab.* 1996; 22: 16-21.
19. O. Heimbürger, P. Stenvinkel, L. Berglund, A. Tranaeus, B. Lindholm. Increased plasma lipoprotein(a) in CAPD is related to peritoneal transport of proteins and glucose. *Nephron.* 1996; 72: 135-144.
20. P. Stenvinkel, L. Berglund, S. Ericsson, A. Alvestrand, B. Angelin and M. Eriksson. Low-density lipoprotein metabolism and its association to plasma Lp(a) in the nephrotic syndrome. *Europ J Clin Invest* 1997; 27: 1691-77.
21. G. Eggertsen, O. Heimbürger, P. Stenvinkel, L. Berglund. Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. *Nephrol Dial Transpl* 1997; 12: 141-144.
22. P. Stenvinkel, J. Bolinder, A. Alvestrand. Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in Type-1 diabetic patients having incipient nephropathy. *Acta Diabetologica* 1997; 34: 10-17.
23. O. Heimbürger, P. Stenvinkel, L. Berglund. Plasma lipoprotein (a) is related to peritoneal albumin losses. *Nephron* 1997; 76: 241.
24. P. Stenvinkel, A Ottosson-Seeberger, K. de Potocki, A. Alvestrand. A calcium channel blocker, amlodipin, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. *Nephrol Dial Transpl* 1997; 12: 1600-1607.
25. P. Stenvinkel, O. Heimbürger, F. Lönnqvist. Serum leptin levels correlate to plasma insulin levels independently of the body fat content in chronic renal failure. *Nephrol Dial Transpl* 1997; 12: 1321-5.
26. O. Heimbürger, F. Lönnqvist, A. Danielsson, J. Nordenström, P. Stenvinkel. Serum immunoreactive leptin concentrations and its relation to the body fat content in chronic renal failure. *J Am Soc Nephrol* 1997; 8: 1423-1430.

27. P. Stenvinkel, O. Heimbürger, C. Tuck, and L. Berglund. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. *Kidney Int.* 1998; 53: 1336-1342.
28. P. Stenvinkel. Leptin - a new hormone of definite interest for the nephrologist. *Nephrol Dial Transpl.* 1998; 13: 1099-1101.
29. P. Stenvinkel, O. Heimbürger, F. Lönnqvist, P. Bány. Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure? *Kidney Int.* 1998; 53: 1430-1431.
30. L. Nordfors, F. Lönnqvist, A. Danielsson, O. Heimbürger, M. Schalling, P. Stenvinkel. Low leptin gene expression and hyperleptinemia in chronic renal failure. *Kidney Int.* 1998; 54: 1267-75.
31. P. Stenvinkel, I. Holmberg, O. Heimbürger, U. Diczfalusy. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. *Nephrol Dial Transpl* 1998; 13: 2594-2600.
32. O. Heimbürger, T. Wang, F. Lönnqvist, P. Stenvinkel. Peritoneal clearance of leptin in CAPD patients. Impact of intraperitoneal insulin. *Nephrol Dial Transpl.* 1999; 14: 723-727.
33. P. Stenvinkel, O. Heimbürger, F. Paultre, U. Diczfalusy, T. Wang, L Berglund, T. Jogestrand. Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. *Kidney Int.* 1999; 55: 1899-1911.
34. P. Stenvinkel, F. Lönnqvist, M. Schalling. Molecular studies of leptin: implications for renal disease. *Nephrol Dial Transpl.* 1999;14:1103-1112.
35. P. Stenvinkel, P. Andersson, T. Wang, B. Lindholm, J. Bergström, J. Palmblad, O. Heimbürger, T. Cederholm. Do ACE-inhibitors suppress TNF- α production in advanced chronic renal failure? *J Int Med*, 1999; 246: 503-507
36. P. Stenvinkel. Leptin and its clinical implications in chronic renal failure. *Mineral Electrolyte Metabolism.* 1999, 25: 298-302
37. P. Stenvinkel, O. Heimbürger, T Jogestrand, A Kärnell, A Samulesson. Does persistent infection with *Chlamydia pneumoniae* increase the risk of atherosclerosis in chronic renal failure? *Kidney Int.* 1999; 55: 2531-2532.
38. E. Efendic, B. Lindholm, J. Bergström, P. Stenvinkel. Starka samband mellan malnutrition, inflammation och arterioskleros vid kronisk njursvikt. *Läkartidningen*, 1999;96: 4538-4542
39. P. Stenvinkel, O Heimbürger. The enigma of increasing serum leptin levels during peritoneal dialysis. *Am J Kidney Dis* 1999; 34: 947-950
40. P. Stenvinkel, O. Heimbürger, T. Wang, B. Lindholm, J. Bergström, C-G. Elinder. Increased serum hyaluronan is strongly associated with the clinical condition of the patient and

predicts death following start of renal replacement therapy. *Am J Kidney Dis* 1999; 34:1083-1088.

41. P. Stenvinkel, B. Lindholm, F. Lönnqvist, K. Katzarski, O. Heimbürger. Increase in serum leptin during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. *J Am Soc Nephrol* 2000;11:1303-1309.

42. M. Suliman, AR. Qureshi , P. Barany, P. Stenvinkel, J.D. Divino, B. Anderstam, O. Heimbürger, B. Lindholm, J. Bergström. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. *Kidney Int* 2000;57: 1727-1735

43. L. Nordfors, O. Heimbürger, F. Lönnqvist, B. Lindholm, J. Helmrich, M. Schalling, P. Stenvinkel. Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. *Kidney Int* 2000;57:1713-1719.

44. P. Stenvinkel, C-G. Elinder, P. Barany. Physical activity promotes health also among dialysis patients. *Int J Cardiol.*2000; 72:299-300.

45. P. Stenvinkel, O. Heimbürger, B. Lindholm, G.A. Kaysen, J. Bergström. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA-syndrome). *Nephrol Dial Transpl* 2000;15:953-960.

46. P. Stenvinkel. Leptin and blood pressure – is there a link? *Nephrol Dial Transpl.* 2000;15:1115-7.

47. P. Stenvinkel, B. Lindholm, O. Heimbürger. New strategies for management of malnutrition in PD patients. *Perit Dial Int.* 2000;20:271-275.

48. P. Stenvinkel, A. Alvestrand, B. Angelin, M. Eriksson. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. *Europ J Clin Invest.* 2000;30:866-870.

49. P. Stenvinkel, B. Lindholm, M. Heimbürger, O. Heimbürger Elevated serum levels of soluble adhesion molecules predict death in predialysis patients: Associations with malnutrition, inflammation and cardiovascular disease. *Nephrol Dial Transpl.* 2000;15:1624-1630.

50. O. Heimbürger, AR Qureshi, WS. Blaner, L. Berglund, P. Stenvinkel. Hand-grip muscle strength, lean body mass and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *Am J Kidney Dis* 2000;36:1213-1225.

51. P. Stenvinkel. Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purif* 2001;19:53-61.

52. P. Barany, P. Stenvinkel, A. Ottosson-Seeberger, A. Alvestrand, J. Roberts, A. Salahudeen. Effect of 6-weeks of vitamin E administration on renal hemodynamic alterations following a single dose of Neoral in healthy volunteers. *Nephrol Dial Transpl*. 2001;16:580-584.
53. P. Stenvinkel. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. *Blood Purif* 2001;19:143-151
54. Chung SH, Stenvinkel P, Bergström J, Lindholm B. Biocompatibility of new PD solutions: What can we hope to achieve? *Perit Dial Int* 2000;20(suppl 5):S57-S67.
55. Chung SH, Stenvinkel P, Heimbürger O, Bergström J, Lindholm B. Prevention and treatment of the malnutrition, inflammation and atherosclerosis (MIA syndrome) in uremic patients. *Pol Arch Med Wewn* 2000;104:645-54.
56. Stenvinkel P. Inflammation and endothelial dysfunction – is there a link? *Nephrol Dial Transpl* 2001; 16: 1968-1971.
57. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to *Chlamydia pneumoniae* seropositivity. *Am J Kidney Dis* 2002;39:274-282
58. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. *Nephrol Dial Transpl* 2001; 16 [Suppl 7]: 36-40
59. Heimbürger O, Stenvinkel P. Estimation of lean body mass by dual-energy x-ray absorptiometry. Reply. *Am J Kidney Dis* 2001;38:221
60. Pecoits-Filho R, Stenvinkel P, Chung S-E, Bergström J, Lindholm B. Malnutrition, inflammation and atherosclerosis (MIA syndrome) in ESRD patients. *Pol Neph and Dialysotherapy* 2001; 5[Suppl 1]: 8-13.
61. Chung SH, Heimbürger O, Stenvinkel P, Bergström J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. *Nephrol Dial Transpl* 2001;16:2240-2245.
62. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn P, Deppish R, Descamps-Latscha B, Henle T, Jörres A, Mass ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: present state of the art. *Int J Artif Org* 2001;24:695-725.
63. Nordfors L, Stenvinkel P, Marchlewska A, Weiss R, Heimbürger O, Bergström J, Lindholm B, Schalling M. Molecular genetics and renal disease: What can we hope to achieve? *Nephrol Dial Transpl* 2002;17[Suppl 3]:S5-S11
64. Stenvinkel P, Chung S-H, Heimbürger O, Lindholm B. Malnutrition, inflammation and atherosclerosis in peritoneal dialysis patients. *Perit Dial Int* 2001;21[Suppl 3]:S144-S149

65. Pecoits-Filho RFS, Araujo MRT, Lindholm B, Stenvinkel P, Abensur H, Romao Jr JE, Marcondes M, Freiria de Oliveria AH, Noronha IL. Association between peritoneal solute transport rate and plasma and dialysate cytokine concentrations in CAPD patients. *Nephrol Dial Transpl* 2002;8:1480-6.
66. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? *Nephrol Dial Transpl* 2002;17 [Suppl 8]:33-8
67. Elinder C-G, Stenvinkel P, Heimbürger O. Dialysbehandling är livsuppehållande – men när skall den påbörjas? *Läkartidningen* 2002; 99: 520-1
68. Stenvinkel P, Barany B, Chung SH, Lindholm B, Heimbürger O. A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. *Nephrol Dial Transpl* 2002;17:1266-1274
69. M. Suliman, Barany B, Divino Filho JC, Qureshi AR, Stenvinkel P, Heimbürger O, Anderstam B, Lindholm B, Bergström J. Influence of nutritional status of plasma and erythrocyte sulfur amino acids, sulfhydryls and inorganic sulfate in end-stage renal disease. *Nephrol Dial Transpl* 2002;17:1050-60
70. Suliman ME, Stenvinkel P, Heimbürger O, Barany P, Lindholm B, Bergström J. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. *Am J Kidney Dis* 2002;40:480-488
71. P. Stenvinkel, Barany P, Heimbürger O, Pecoits-Filho, B Lindholm. Mortality, malnutrition and atherosclerosis in end-stage renal disease: What is the role of interleukin-6? *Kidney Int* 2002; 61 [Suppl 80]: S103-S108.
72. B. Lindholm, O Heimbürger, P. Stenvinkel What are the causes and consequences of protein-energy malnutrition in chronic renal failure? *Am J Kidney Dis* 2002;39:422-425
73. R. Pecoits-Filho, P. Barany, B. Lindholm, O. Heimbürger and P. Stenvinkel. Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. *Nephrol Dial Transpl* 2002;17:1684-1688
74. P Stenvinkel, A Alvestrand. Inflammation in end-stage renal disease: sources, consequences and therapy. *Seminar Dial* 2002;15:330-338
75. J. Himmelfarb, P. Stenvinkel, A. Ikizler, RM Hakim. The elephant of uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int* 2002;62:1524-38
76. P. Stenvinkel, P Barany. Anaemia, epoetin resistance and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. *Nephrol Dial Transpl* 2002; 17[Suppl 5];32-7

77. Nascimento MM, Pecoits-Filho R, Lindholm B, Riella M, Stenvinkel P. Inflammation, malnutrition and atherosclerosis (MIA) in end-stage renal disease: a global perspective. *Blood Purif* 2002;20:454-458.
78. P. Stenvinkel, C Wanner, T Metzger, O Heimbürger, F Mallamaci, G Tripepi, L Malatino, C Zoccali. Inflammation and outcome in end-stage renal disease: impact of gender. *Kidney Int* 2002;62:1791-8
79. P. Stenvinkel, Barany P. Pure red-cell aplasia orsakad av anti-erythropoietin antikroppar – ovanlig men allvarlig biverkan vid behandling med rekombinant humant erythropoietin hos njursjuka. *Läkartidningen* 2002;99:4162-3.
80. Pecoits-Filho RFS, Nordfors L, Heimbürger O, Lindholm B, Anderstam B, Marchlewska A, Stenvinkel P. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. *Europ J Clin Invest* 2002;32: 811-7.
81. Pecoits-Filho RFS, Lindholm B, Stenvinkel P. The malnutrition, inflammation and atherosclerosis (MIA) syndrome - the heart of the matter. *Nephrol Dial Transpl* 2002;17[Suppl 11]:28-31
82. Stenvinkel P. Interactions between inflammation, oxidative stress and endothelial dysfunction in end-stage renal disease. *J Renal Nutr* 2003;13:144-8
83. Löwbeer C, Stenvinkel P, Pecoits-Filho RFS, Heimbürger O, Lindholm B, Gustavsson SA, Seeberger A. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Int Med* 2003;253:153-160.
84. Chung SH, Heimbürger O, Qureshi AR, Stenvinkel P, Bergström J, Lindholm B. Association between residual renal function, inflammation, and patient survival in new peritoneal dialysis patients. *Nephrol Dial Transpl* 2003;18:590-7.
85. Chung SH, Heimbürger O, Lindholm B, Stenvinkel P. Chronic inflammation in PD patients. *Contrib Nephrol* 2003;140:104-11
86. Suliman ME, Stenvinkel P, Barany P, Heimbürger O, Anderstam B, Lindholm B. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: Influence of hypoalbuminemia, malnutrition, inflammation and diabetes mellitus. *Am J Kidney Dis* 2003;41[Suppl 2]; S89-95.
87. Vanholder, R., de Smet R., Glorieux G, Argiles, A, Baurmeister U, Brunet P, Clark W, Cohen G, de Deyn PP, Deppish R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy, ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr, B, Stenvinkel P, Tetta C, Wanner C, Zidek W. Review on uremic toxicity: Classification, concentration, and interindividual variability. *Kidney Int* 2003;63:1934-43.

88. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimbürger O, Barany P, Hoff C, Lindholm B, Schalling M, Nordfors L. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. *Kidney Int* 2003;84:172-176
89. Pecoits-Filho R, Nordfors L, Lindholm B, Hoff C, Schalling M, Stenvinkel P. Genetic approached in the clinical investigation of complex disorders: malnutrition, inflammation and atherosclerosis (MIA) as a prototype. *Kidney Int* 2003;84:162-167
90. Chung SH, Heimbürger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. *Perit Dial Int* 2003, 23: 174-183
91. R Pecoits-Filho, P Bárány, O Heimbürger, B Lindholm, M Suliman, I Fehrman-Ekholm, P Stenvinkel. Associations between circulating inflammatory markers and residual renal function in CRF patients. *Am J Kidney Dis* 2003;41:1212-1218
92. Suliman M, Heimbürger O, Bárány P, Anderstam A Pecoits-Filho R, Ayala ER, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting dialysis therapy. *J Am Soc Nephrol* 2003;14:1614-22
93. T Bratel, S Ljungman, M Runold, P Stenvinkel. Renal function in hypoxemic chronic obstructive pulmonary disease. Effects of long-term oxygen treatment. *Resp Med* 2003; 97: 308-316
94. F Locatelli, B Canaud, K Eckardt, P Stenvinkel, C Wanner, C Zoccali. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrol Dial Transpl* 2003; 18:1272-1280
95. Stenvinkel P, Pecoits-Filho R, Lindholm B. Leptin, ghrelin and pro-inflammatory cytokines - compounds with nutritional impact in chronic kidney disease? *Adv Ren Repl* 2003;10:332-45
96. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in renal disease. *Nephrol Dial Transpl* 2003;18:1042-1045
97. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. *J Am Soc Nephrol* 2003;14:1927-1939
98. F Locatelli, B Canaud, K Eckardt, P Stenvinkel, C Wanner, C Zoccali. The importance of diabetic nephropathy in current nephrological practice. *Nephrol Dial Transpl* 2003; 18:1716-1725

99. Pecoits-Filho R, Lindholm B, Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia. *Eur J Clin Invest* 2003;33:527-8
100. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Andersson S, Schalling M, Barany P, Lindholm L, Nordfors L. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. *Kidney Int* 2004;65:274-81
101. Martola L, Elinder C-G, Stenvinkel P. Varför får njursjuka ett hjärta av sten? Störd kalciumfosfatbalans och kronisk inflammation viktiga orsaker. *Läkartidningen* 2003;50:4180-3
102. Rodriguez Ayala E, Pecoits-Filho R, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. *Nephrol Dial Transpl* 2004;19:421-6
103. Marchlewska A, Stenvinkel P, Lindholm L, Danielsson A, Pecoits-Filho R, Lönnqvist L, Schalling M, Heimbürger O, Nordfors L. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. *Kidney Int* 2004;66:46-50
104. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologists? *Nephrol Dial Transpl* 2003;18[Suppl 8] 17-22
105. Pecoits-Filho R, Stenvinkel P, Heimbürger O, Lindholm B. Beyond the membrane – The role of new PD solutions in enhancing global biocompatibility. *Kidney Int* 2003; 64 [Suppl 88], S124-S132
106. Stenvinkel P, Dizzfalusy U, Lindholm B, Heimbürger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. *Nephrol Dial Transpl* 2004;19:972-6
107. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. *Adv Ren Repl Ther* 2003;10:155-169
108. Pecoits-Filho R, Stenvinkel P, Wang A, Heimbürger O, Lindholm B. Chronic inflammation in peritoneal dialysis: The search for the Holy Grail? *Perit Dial Int* 2004;24:327-339
109. Chung SH, Heimbürger O, Lindholm B, **Stenvinkel P**. Chronic inflammation in PD. *Contrib Nephrol* 2003;140:104-111
110. Hayashi SY, Brodin LA, Alvestrand A, Lind B, **Stenvinkel P**, Do Nascimento MM, Qureshi AR, Saha S, Lindholm B, Seeberger A. Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. *Nephrol Dial Transpl* 2004;19:1497-1506

111. Stenvinkel P, Lindholm B, Heimbürger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. *Seminal Dial* 2004;17:505-515.
112. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease and poor outcome in hemodialysis patients. *Hemodial Int* 2004;8:118-129
113. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and Non-traditional Risk Factors as Contributors to Atherosclerotic Cardiovascular Disease in End-Stage Renal Disease. *Scand J Nephrol Urol* 2004;38:405-416
114. Stenvinkel P, Heimbürger O, Lindholm L. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. *Nephrol Dial Transpl* 2004;19:2181-3
115. Pecoits-Filho R, Simone Goncalves S, Silvio Barberato S, Bignelli A, Lindholm B, Riella MC, Stenvinkel P. Impact of residual renal function on volume status in chronic renal failure. *Blood Purif* 2004;22:285-292
116. Nascimento M, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Heimbürger O, Cederholm T, Lindholm L, Bárány P. Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. *Nephrol Dial Transpl* 2004;19:1823-8
117. Suliman ME, Stenvinkel P, Qureshi AR, Barany P, Heimbürger O, Anderstam B, Alvestrand A, Lindholm B: Hyperhomocysteinemia in relation to plasma free amino acids and inflammation in patients with end-stage renal disease. *Am J Kidney Dis* 2004;44:455-65
118. Axelsson J, Qureshi AR, Suliman ME, Hirokazu Honda H, Pecoits-Filho R, Heimbürger O, Lindholm B, Cederholm T, Stenvinkel P. Visceral fat mass as a contributor to inflammation in end-stage renal disease. *Am J Clin Nutr* 2004, 80:1222-9
119. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Tommy Cederholm T, Girndt M. IL-10, IL-6 and TNF- α : central factors in the altered cytokine network of uremia - the good, the bad and the ugly. *Kidney Int* 2005;67:1216-33
120. Nascimento MM, Pecoits-Filho R, Qureshi AR, Hayashi SY, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Lindholm B, Riella MC. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian hemodialysis patients: a prospective study. *Nephrol Dial Transpl* 2004;19:2803-9
121. Yao Q, Axelsson J, Heimbürger O, Stenvinkel P, Lindholm B. Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences. *Minerva Urol Nephrol* 2004;56:237-48
122. Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. *J Ren Nutr*. 2005;15:131-6.

- 123.Nascimento M, Suliman M, Bruchfeld A, Hayashi S, Manfro R, Qureshi AR, Pecoits-Filho R, Pachaly M, Renner L, Stenvinkel P, Riella M, Lindholm B. The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels *Nephrol Dial Transpl* 2004;19:3112-6
- 124.Suliman M, Barany P, Kalanthar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia – a puzzling and conflicting story. *Nephrol Dial Transpl* 2005;20:16-21
- 125.Maruyama Y, Lindholm B, Stenvinkel P. Inflammation and oxidative stress in ESRD – the role of myeloperoxidase. *J Nephrol* 2004; 17(Suppl 8): S72-6
- 126.Stenvinkel P, Lindholm B. CRP in end-stage renal disease: are there reasons to measure it? *Blood Purif* 2005;23:72-8
- 127.Rodriguez-Ayla, E, Anderstam B, Suliman M, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P. Enhanced RAGE-mediated NFκB stimulation in inflamed hemodialysis patients. *Atherosclerosis* 2005;180:333-340
- 128.Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M and Nordfors L. Low serum fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney Int* 2005: 67:2383-92
- 129.Martola L, Barany P, Stenvinkel P. Why do dialysis patients get a heart of stone and bone of china? *Blood Purif* 2005;23:203-210
- 130.Snaedal Jonsdottir S, Stenvinkel P, Barany P. Val av dialysform – ett avgörande beslut. Peritonealdialys är bättre för patienten och billigare för samhället. *Läkartidningen* 2005;5:281-2
- 131.Yao Q, Axelsson J, Nordfors, L, Heimbürger O, Qureshi AR, Barany P, Lindholm B, Lönnqvist F, Schalling M, Stenvinkel P. Peroxisome proliferator-activated receptor α polymorphisms in relation to inflammation and survival in end-stage renal disease patients starting renal replacement therapy. *Atherosclerosis* 2005;182:105-111
- 132.Yao Q, Axelsson J, Stenvinkel P, Lindholm B. Chronic systemic inflammation in dialysis patients: An update on causes and consequences. *ASAIO JOURNAL* 50 (6): LII-LVII NOV-DEC 2004
- 133.Stenvinkel P, Pecoits-Filho R, Lindholm B for the DialGene Consortium. Gene-polymorphism-association studies in end-stage renal disease patients related to the nutrition-inflammation axis. *Semin Nephrol*, 2005;18:231-239
- 134.Pecoits-Filho R, Sylvestre LC, Stenvinkel P. Chronic kidney disease and inflammation in pediatric patients: from bench to playground. *Pediatr Nephrol* 20;714-20, 2005 β

135. Gillerot G, Goffon E, Michel C, Evenepoel P, van Biesen W, Tintillier M, Stenvinkel P, Heimbürger O, Lindholm B, Nordfors L, Robert A, Devuyst O. Genetic and clinical factors influence baseline permeability of the peritoneal membrane. *Kidney Int* 67:2477-87:2005
136. Stenvinkel P. Inflammation in end-stage renal disease – a fire that burns within. *Contrib Nephrol* 149:185-99, 2005
137. Maryuama Y, Stenvinkel P, Lindholm B. The role of interleukin-1b in the development of malnutrition in chronic renal failure patients. *Blood Purif* 23:275-81, 2005
138. Nascimento MM, Bruchfeld A, Suliman M, Hayashi SY, Pecoits-Filho R, Manfro RC, Pachaly MA, Rener L, Stenvinkel P, Riella MC, Lindholm B. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. *Braz J Med Biol Res* 2005;38:783-8
139. Nordfors L, Lindholm B, Stenvinkel P. End-stage renal disease – not an equal opportunity disease. *J Int Med* 258:1-12, 2005
140. Bolton K, Beddhu S, Campese VM, Chavers BM, Cheung AK, Churchill DN, Goldstein-Fuchs J, Herzog CA, Henrich W, King K, Kronenberg F, Miholics BS, Painter PL, Parekh R, Roberts MS, Stehman-Breen C, Stenvinkel P, Wali R, Weiss MF. K/DOQI clinical guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis* 45(Suppl 3); 2005
141. Stratton R, Bircher G, Fouque D, Stenvinkel P, de Mustsert R, Engfer M, Elia M. Multi-nutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *Am J Kidney Dis* 46:387-405, 2005
142. Maruyama Y, Nordfors L, Stenvinkel P, Heimbürger O, Barany P, Pecoits-Filho R, Axelsson J, Hoff C, Holmes C, Schalling M, Lindholm B. IL-1 gene cluster polymorphisms are associated with nutritional status and inflammation in end-stage renal disease. *Blood Purif* 2005;23:384-393
143. Kalantar-Zadeh K, Stenvinkel P, Bross R, Khawar OS, Ramohan M, Olman S, Benner D. Kidney insufficiency and nutrient-based modulation of inflammation. *Curr Opin Clin Metab Care*. 8:388-396, 2005
144. Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Barany P, Heimbürger O, Anderstam B, Rodriguez-Ayla E, Divino Filho J, Alvestrand A, Lindholm B. Inflammation contributes to low plasma amino acid levels in patients with chronic kidney disease. *Am J Clin Nutr* 2005;82:342-9
145. Heimbürger O, Stenvinkel P. Adipokines in chronic kidney disease – fat tissue gives nephrologists a message. *Perit Dial Int* 2005;25:340-2

- 146.Pupim K, Heimbürger O, Qureshi AR, Ikizler A, Stenvinkel P. Accelerated loss of lean body mass in incident chronic dialysis patients with diabetes mellitus. *Kidney Int* 2005;68:2368-74
- 147.Yao Q, Wang X, Chung SH, Pecoits-filho R, Stenvinkel P, Wang T, Heimbürger O, Lindholm B. The role of peritoneal dialysis in renal replacement therapy: an update on medical aspects. *Panminerva Med.* 2005 Mar;47(1):19-30
- 148.Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Barany P. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. *Am J Kidney Dis* 2005 Oct;46(4):628-34
- 149.Suliman ME, Stenvinkel P, Lindholm B. Is Hyperhomocysteinemia a Contributor to Atherosclerosis in Chronic Kidney Disease Patients? *Nephron Clin Practice* 2005; 101:c187-9
- 150.Holmén C, Elsheikh E, Stenvinkel P, Qureshi AR, Pettersson E, Jalkanen S, Sumitran-Holgersson S. Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. *J Am Soc Nephrol* 2005;16:3110-3120
- 151.Stenvinkel P, Cheung A, Heinrich W. In reply. *Am J Kidney Dis* 2005;46:369
- 152.Pupim LB, Flakoll PJ, Majchrzak KM, Guy DLA, Stenvinkel P, Ikizler TA. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. *Kidney Int* 2005;68:1857-65
- 153.Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho, Stenvinkel P, Lindholm B. Serum albumin, C-reactive protein, interleukin-6 and fetuin-A as predictors of malnutrition, cardiovascular disease and mortality in patients with end-stage renal disease. *Am J Kidney Dis* 2006;47:139-48
- 154.Rodriguez-Ayala E, Yao Q, Holmén C, Lindholm B, Sumitran-Holgersson S, Stenvinkel P. Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. *Blood Purif* 2005;24:196-202
- 155.P Stenvinkel. Inflammation in end-stage renal disease – the hidden enemy. *Nephrology* 2006;11:36-41
- 156.Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Barany P, Lönnqvist F, Lindholm F, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney Int* 2006;69:596-64
- 157.Axelsson J, Barany P, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P. Reply from the authors. *Kidney Int* 2005; 68: 2916

158. Nascimento MM, Suliman ME, Murayama Y, Hayashi SY, Stenvinkel P, Riella MC, Lindholm B et al. Effect of high-dose of thiamine and pyridoxine on advanced glycation end-products and other oxidative stress markers in hemodialysis patients: a randomized placebo controlled study. *J Ren Nutr*, 2006;16:119-24
159. Stenvinkel P, Rodriguez-Ayla E, Massy Z, Qureshi AR, Barany P, Fellström B, Heimbürger O, Lindholm B, Alvestrand A. Statin treatment and diabetes mellitus affect MPO-activity in maintenance hemodialysis patients. *Clin J Am Soc Nephrol* 2006;1:281-287
160. Axelsson J, Qureshi AR, Divino-Filho J, Barany P, Heimbürger O, Lindholm B, Stenvinkel P. Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease? *Eur J Clin Nutr*. 2006;60:718-26
161. Suliman M, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P Soluble adhesion molecules in end-stage renal disease - A predictor of outcome. *Nephrol Dial Transpl* 2006;21:1603-10
162. Lindholm B, Stenvinkel P. In reply. *Blood Purif* 2006;24:233
163. Suliman ME, Stenvinkel P, Barany P, Qureshi RE, Lindholm B. Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. *Semin Nephrol* 2006;26:14-9
164. Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Barany P. In Reply, *Am J Kidney Dis* 2006;47:372.
165. Pecoits-Filho, R, Carvalho MJ, Stenvinkel P, Lindholm, B, Heimbürger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. *Perit Dial Int* 2006;26:53-63
166. Carrero JJ, Axelsson J, Avesani CM, Heimbürger O, Lindholm B, Stenvinkel P. Being an inflamed peritoneal dialysis patient – a Dantes journey. *Contrib Nephrol* 2006;150:144-151
167. Axelsson, J, Carrero JJ, Avesani CM, Heimbürger O, Lindholm B, Stenvinkel P. Adipokine signalling in the peritoneal dialysis patient. *Contrib Nephrol* 2006;150: 166-173
168. Stenvinkel P. C-reactive protein – does it promote vascular disease? *Nephrol Dial Transpl* 2006; 21 2718-2720
169. Axelsson J, Heimbürger O, Stenvinkel P. Adipose tissue and inflammation in chronic kidney disease. *Contrib Nephrol* 151;165-174, 2006
170. Suliman ME, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimbürger O, Vonesh EF, Lindholm B. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrol Dial Transpl* 2007;22:209-217

171. Buhlin K, Barany P, Heimbürger O, Stenvinkel P, Gustafsson A. Oral infections and oral health in end stage renal disease patients. *Oral Health Prev Dent* 2007;5:235-44
172. Axelsson J, Holger J Moller, Witasp A, Qureshi AR, Heimbürger O, Barany P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with chronic kidney disease. *Am J Kidney Dis* 2006;48:916-25
- 173.** Suliman ME, Johnson RJ, García-López E, Qureshi AR, Molinari H, Carrero JJ, Heimbürger O, Bárány P, Axelsson J Lindholm B Stenvinkel P. J-shaped mortality relationship for uric acid in chronic kidney disease. *Am J Kidney Dis* 2006;48:761-71
174. Wang X, Axelsson J, Nordfors L, Qureshi AR, Avesani C, Barany P, Schalling M, Heimbürger O, Lindholm B, Stenvinkel P. Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. *Nephrol Dial Transpl* 2007;22:196-202
175. Axelsson J, Devuyst O, Nordfors L, Heimbürger O, Stenvinkel P, Lindholm B. Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney Int* 2006;70:S138-145
176. Martins C, do Nascimento MM, Pecoits-Filho R, Leining C, Goncalves LF, Fuerbringer R, Stenvinkel P, Lindholm B, Riella MC. Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. *J Renal Nutr* 2007;17:132-7
177. Barany P, Suliman M, Stenvinkel P, Qureshi AR, Lindholm B. Hyperhomo-cysteinemia and cardiovascular mortality in ESRD patients. *Ann Acad Med Gedan* 200535 (Suppl 10) 37-42
178. Avesani CM, Carrero JJ, Axelsson J, Qureshi AR, Lindholm B, Stenvinkel P. Inflammation and wasting in chronic kidney disease: Partners in crime. *Kidney Int* 2006;104:S8-S13
179. Axelsson, Lindholm B, Stenvinkel P. Response to “resistin letters”. *Kidney Int* 2006;70:1372
180. Hagdoost S, Maruyama Y, Pecoits-Filho R, Heimbürger O, Seeberger A, Anderstam B, Suliman ME, Czene S, Lindholm B, Stenvinkel P, Harms-Ringdahl M. Elevated serum 8-Oxo-dG in hemodialysis patients: A marker of systemic inflammation? *Antioxid Redox Signal* 2006;8:2169-73
181. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimbürger O, Lindholm B, Stenvinkel P. Comparisons of

nutritional and inflammatory markers between male and female dialysis patients with reduced appetite. *Am J Clin Nutr* 2007;85:695-701

182. Axelsson J, Devuyst O, Nordfors L, Heimbürger O, Stenvinkel P, Lindholm B. Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney Int* 2006;70:S138-45

183. Axelsson J, Witasap A, Carrero JJ, A Qureshi AR, Suliman ME, Heimbürger O, Bárány P, Lindholm B, Alvestrand A, Schalling M, Nordfors L and Stenvinkel P. Circulating levels of visfatin/pre-B cell colony-enhancing factor-1 are influenced by genotype and are associated with markers of endothelial dysfunction and survival in patients with chronic kidney disease (CKD). *Am J Kidney Dis* 2007;49:237-44

184. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Barany P, Heimbürger O, Lindholm B. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. *Clin Nephrol* 2006;66:418-425

185. Avesani CM, Heimbürger O, Stenvinkel P, Lindholm B. Nutritional aspects of adult patients treated with chronic peritoneal dialysis. *J Bras Nephrol* 2006;28:232-8

186. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman ME, Lindholm B, Heimbürger O, Barany P, Alvestrand A, Qureshi AR, Ekstrom T, Schalling M. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? *J Int Med* 2007;261:488-99

187. Witasap A, Nordfors L, Lindholm B, Stenvinkel P. Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. *J Renal Nutr* 2007;17:17-22

188. Axelsson J, Carrero JJ, Lindholm B, Heimbürger O, Stenvinkel P. Malnutrition in patients with end-stage renal disease – anorexia, cachexia and catabolism. *Current Nutr & Food Science* 2007;37-46

189. Cederholm, T, Persson, M, Andersson, Stenvinkel, P, Nordfors, L, Madden, J, Vedin, I, Wretling, B, Grimble, R, Palmblad, J. Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. *J Int Med* 2007;262:215-23

190. Grahl D, Axelsson J, Nordfors, L, Heimbürger O, Barany P, Qureshi AR, Watanabe M, Suliman M, Riella MC, Lindholm B, Stenvinkel P, Pecoits-Filho R. Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. *Blood Purif* 2006;25:210-218

191. Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B. Overestimation of advanced oxidation protein products

in uremic plasma due to presence of triglycerides and other endogenous factors, *Clin Chim Acta*. 2007 Apr;379(1-2):87-94.

192.Yilmaz M, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Low grade inflammation in chronic kidney disease before the start of renal replacement therapy: Sources and consequences. *Clin Nephrol* 2007;68:1-9

193.Suliman M, Lindholm B, Barany P, Qureshi AR, Stenvinkel P. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. *Semin Dial* 2007; 20;523-29

194.Heimbürger O, Stenvinkel P. Statins to treat chronic inflammation in dialysis patients – is it feasible? *Perit Dial Int* 2007;27:254-7

195.Kato S, Lindholm B, Axelsson J, Qureshi AR, Barany P, Heimbürger O, Gustafsson J-Å, Stenvinkel P, Nordfors L. Association between estrogen receptor a (Era) gene polymorphism and mortality in female end-stage renal disease patients. *Nephrol Dial Transpl* 2008;22:2571-7

196.Girndt M, Stenvinkel P, Ulrich C, Axelsson J, Nordfors L, Barany P, Carrero, JJ, Heine, GH, Kaul, H, and Köhler, H. Influence of cytokine gene polymorphisms on erythropoietin dose requirements in chronic hemodialysis patients. *Nephrol Dial Transpl* 2008;22:3586-92

197.Garzia-Lopez E, Carrero JJ, Suliman M, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease patient undergoing peritoneal dialysis. *Perit Dial Int* 2007;27:S205-S209

198.Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Raj D. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney Int* 2007; 72:549-56

199.Chung SH, Stenvinkel P, Lindholm B, Avesani CM: Identifying and managing malnutrition stemming from different causes.. *Perit Dial Int* 2007;27:S239-S244

200.Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm B and Suliman ME. Plasma pentraxin 3 in chronic kidney disease patients: Associations with renal function, protein-energy wasting, cardiovascular disease and mortality. *Clin J Am Soc Nephrol* 2007;2:889-897

201.Wanner C, Richardsson D, Fouque D, Stenvinkel P. OPTA Influence of inflammation/infection on anaemia therapy in haemodialysis patients. *Nephrol Dial Transpl* 2007; 22 (Suppl 3); ii7-iii12

202.Carrero JJ, Qureshi AR, Axelsson, J, Yilmaz M, Rehnmark S, Witt M, Barany P, Heimbürger O, Suliman M, Stenvinkel P. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *J Int Med* 2007;262:690-701

203. Carrero JJ, Heimbürger O, Lindholm B, Stenvinkel P. Increased ghrelin levels - another piece of the complicated puzzle of uremia anorexia. In Press Am J Clin Nutr 2007
204. Yilmaz I, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J. Markedly elevated circulating asymmetric dimethyl-arginine (ADMA) levels in proteinuric patients with secondary amyloidosis correlate with endothelial dysfunction. Is protein turnover in nephritic syndrome a novel risk CVD risk factor? J Am Soc Nephrol 2008;19:388-95
205. Stenvinkel P. Hjärt-kärlsjukdom ökar risken för njursvikt. Läkartidningen 2007;36:2495
206. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Masy Z, Mitch W, Pineda E, Stenvinkel P, Trevinho-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008;73:391-8.
207. Stenvinkel P, Lindholm B. Resolved: Being fat is good for dialysis patients – the Godzilla effect (Con). J Am Soc Nephrol 2008 Jun;19(6):1062-4.
208. Carrero JJ, Stenvinkel P, Fellström B, Qureshi AR, Heimbürger O, Barany P, Lindholm B, Soveri I, Nordfors L, Shiels P. Telomere attrition is associated to inflammation, low fetuin-A levels and high mortality in prevalent hemodialysis patients. J Int Med 2008;263:302-312
209. Axelsson J, Wang X, Ketteler M, Qureshi AR, Heimbürger O, Bárány P, Lindholm B, Nordfors L, Stenvinkel P. Is α 2-Heremans-Schmid glycoprotein/fetuin-A associated with aspects of the metabolic syndrome in patients with chronic kidney disease? Am J Nephrol 2008;28:669-676
210. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Short term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3:61-8
211. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Masy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505-521
212. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transpl 2008 May;23(5):1621-7

- 213.Yilmaz MI, Saglam, M, Carrero, JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. *Nephrol Dial Transpl* 2008;23:959-65
- 214.Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vura A, Ikizler TA, Stenvinkel P, Lindholm B. Serum Fetuin-A concentration and endothelial dysfunction in chronic kidney disease. *Nephron Clin Pract* 2008;108:c233-c240
- 215.Axelsson J, Stenvinkel P. Role of fat mass and adipokines in chronic kidney disease. *Curr Opin Nephrol Hypertens* 2008;17:25-31
- 216.Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J, Lindholm B. A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. *Clin Nephrol* 2007;68:295-301
- 217.Carrero JJ, Aguilera A, Stenvinkel P, Gil F, Selgas R, Lindholm B. Appetite disorders in uremia. *J Renal Nutr* 2008;18:107-113
- 218.Pachaly MA, Nascimento MM, Suliman M, Hayashi SY, Riella MC, Manfro RC, Stenvinkel P, Lindholm B, Interleukin-6 is a better predictor of mortality compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. *Blood Purif* 2008;26:204-210
- 219.Bruchfeld A, Qureshi, AR Lindholm B Barany P Yang LH, Stenvinkel P, Tracey K High Mobility Group Box Protein-1 correlates strongly with renal function in Chronic Kidney Disease (CKD). *Mol Med* 2008;14:109-115
- 220.Stenvinkel P, Ekström T. Epigenetics - a helpful tool to better understand processes in clinical nephrology? *Nephrol Dial Transpl* 2008;23:1493-6
- 221.Suliman ME, Qureshi AR, Carrero JJ, Bárány B, Yilmaz MI, Snaedal-Jonsdottir S, Alvestrand A, Heimbürger O, Lindholm L and Stenvinkel P. The long pentraxin PTX-3 in prevalent hemodialysis patients: Associations with co-morbidities and mortality. *QJM*. 2008 May;101(5):397-405
- 222.Matsubara K, Mohamed E Suliman ME, Abdul Rashid Qureshi AR, Axelsson J, Martola L, Heimbürger O, Barany P, Stenvinkel P, Lindholm B. Bone mineral density in end-stage renal disease patients: association with malnutrition, inflammation, cardiovascular disease and mortality. *Blood Purif* 2008;26:284-90

223. Luttropp K, Stenvinkel P, Carrero JJ, Pecoits-Filho R, Lindholm B, and Nordfors L. Understanding the role of genetic polymorphisms in chronic kidney disease. *Pediatr Nephrol* 2008 Nov;23(11):1941-9
224. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, Tong M, Heimbürger O, Barany P, Alvestrand A, Lindholm B, Stenvinkel P. Novel links between the long pentraxin PTX3, endothelial dysfunction and albuminuria in early and advanced chronic kidney disease. *Clin J Am Soc Nephrol*. 2008 Jul;3(4):976-85.
225. Carrero JJ, Shiels PG, Stenvinkel P. The impact of telomere biology as a mortality risk factor in chronic kidney disease. *Am J Kidney Dis* 2008;51:1076-77
226. Watanabe M, Suliman ME, Qureshi AR, Garcia-Lopez, E Bárány P, Heimbürger O, Stenvinkel P and Lindholm B. Consequences of low plasma histidine in CKD patients: Associations with inflammation, oxidative stress and mortality. *Am J Clin Nutr* 2008;87:1860-6
227. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney disease. How can we treat it? *Blood Purif* 2008;26:291-9
228. Stenvinkel P, Ekström T. Epigenetics and the uremic phenotype – a matter of balance. *Contrib Nephrol* 2008;161:55-62.
229. Sjövall P, Johansson B, Belazi D, Stenvinkel P, Lindholm B, Lausmaa J, Schalling M. TOF-SIMS analysis of adipose tissue from patients with chronic kidney disease, *Applied Surface Science* 2008 In Press
230. Anderstam B, Bragfors-Helin A-C, Valli A, Stenvinkel P, Lindholm B, Suliman ME. Modification of the oxidative stress biomarker AOPP assay; application in uremic samples. *Clin Chim Acta* 2008 Jul 17;393(2):114-8.
231. Marangon N, Lindholm B, Stenvinkel P. Nonphosphate-binding effects of sevelamer – are they of clinical relevance? *Semin Dial*. 2008 Sep-Oct;21(5):385-9
232. Chmielewski, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease – reverse epidemiology and therapeutic approach. *J Nephrol*. 2008 Sep-Oct;21(5):635-44.
233. Chmielewski M, Stenvinkel P, Luttropp K, Suliman ME, Qureshi AR, Carrero JJ, Barany P, Heimbürger O, Nordfors L, Lindholm B. Lipoprotein lipase 1595 c/g and hepatic lipase -480 c/t polymorphisms--impact on lipid profile in incident dialysis patients. *Blood Purif*. 2008;26(6):555-60.
234. Carrero JJ, Chmielewski M, Axelsson J, Snaedal-Jonsdottir, Heimbürger O, Barany P, Suliman ME, Lindholm B, Stenvinkel P, Qureshi AR. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. *Clin Nutr* 2008; 27:557-64

235. Yao Q, Pawlaczyk K, Rodríguez Ayala E, Styszynski A, Breborowicz A, Heimbürger O, Qian JQ, Stenvinkel P, Lindholm B, Axelsson J. The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. *Nephron Exp Nephrol*. 2008;109(2):e71-8.
236. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J, Abu-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, De Deyn PP, Drüeke T, Fliser D, Herget-Rosenthal S, Hörl W, Jankowski J, Jörres A, Massy ZA, Mischak H, Perna A, Rodriguez M, Spasovski G, Stegmayr B, Stenvinkel P, Thornalley P, Vanholder R, Wanner C, Wiecek A, Zidek W. A bench to bedside view of uremic toxins. *J Am Soc Nephrol*. 2008 May;19(5):863-70
237. Valli A, Carrero JJ, Qureshi AR, Garibotto G, Barany B, Axelsson J, Bengt Lindholm B, Stenvinkel P, Anderstam B and Suliman ME. The increase of serum S-adenosylhomocysteine, but not homocysteine, is associated with cardiovascular disease in chronic kidney disease patients. *Clin Chim Acta*. 2008 Sep;395(1-2):106-10
238. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo Se, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. *Clin J Am Soc Nephrol* 2008;3:1526-1533
239. Lee SMK, Lee AL, Winters TJ, Tam E, Jaleel M, Stenvinkel P, Johnsson RJ. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. *Am J Nephrol* 2009 11;29(2):79-85
240. Suliman ME, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease patients. *Saudi J Kidney Dis Transpl*. 2008 May-Jun;19(3):329-45.
241. Metry G, Stenvinkel P, Qureshi AR, Carrero JJ, Yilmaz MI, Bárány P, Snaedal S, Heimbürger O, Lindholm B and Suliman ME. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent hemodialysis patients. *Eur J Clin Invest* 2008;38:804-11
242. Axelsson J, O'Byrne SM, Blane WS, Carrero JJ, Annette Bruchfeld A, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P. Serum retinol binding protein concentration and its association with uremic dysmetabolism in non-diabetic end-stage renal disease. *Am J Nephrol* 2009;29:447-453
243. Chmielewski M, Stenvinkel P, Luttrupp K, Suliman ME, Qureshi AR, Carrero JJ, Barany P, Heimbürger O, Nordfors L, Lindholm B. LPL 1595 C/G and HL -480 C/T polymorphisms - impact on lipid profile in incident dialysis patients. *Blood Purif* 2008;26: 555-560

244. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány B, Heimbürger O, Marrón B, George Metry, Snaedal S, Lindholm B, Egido J, Stenvinkel P and Blanco-Colio LM. Additive effects of soluble TWEAK and inflammation on mortality in hemodialyzed patients. *Clin J Am Soc Nephrol* 2009 Jan;4(1):110-8.
245. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Barany P, Heimbürger O, Stenvinkel P. Low serum testosterone increases mortality risk in male dialysis patients. *J Am Soc Nephrol* 2009 Mar;20(3):613-20
246. Carrero JJ, Brodin L, Lindholm B, Stenvinkel P. Adiponectin in chronic kidney disease - Dr. Jekyll and Mr. Hyde. *Kidney Int* 2009;75:120-1
247. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G. Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. *Nephrol Dial Transplant*. 2008 Dec;23(12):3731-7.
248. Muntinghe F, Verduijn M, Grootendorst D, Carrero JJ, Qureshi AR, Luttrupp K, Nordfors L, Lindholm B, Brandenburg V, Stenvinkel P, Boeschoten E, Krediet R, Navis G, Dekker F. CC-chemokine receptor 5 deletion (CCR5Δ32) polymorphism protects against increased mortality rate seen in dialysis patients with chronic inflammation. *J Am Soc Nephrol* 2009 Jul;20(7):1641-9
249. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/ NAMPT. A novel marker of endothelial damage? *Clin Transpl* 2009; 23:241-8
250. Avesani CM, Kamimura MA, Utaoka S, Pecoits-Filho R, Nordfors L, Stenvinkel P, Lindholm B, Draibe SA, Cuppari L. Is UCP2 gene polymorphism associated with decreased resting energy expenditure in nondialyzed chronic kidney disease patients? *J Ren Nutr*. 2008 Nov;18(6):489-94.
251. Qunying G, Zheng H, Bárány P, Qureshi AR, Snaedal S, Heimbürger O, Stenvinkel P, Bengt Lindholm B, Axelsson J. N-terminal pro-brain natriuretic peptide independently predicts protein-energy wasting and is associated with all-cause mortality in prevalent HD patients. *Am J Nephrol* 2009;29:516-523
252. Stenvinkel P, Ekström T. Does the uremic milieu affect the epigenotype? *J Renal Nutr* 2009; 19:82-5

253. Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B. Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. *Curr Opin Lipid* 2009;20:3-9
254. Carrero JJ, Park S-H, Axelsson J, Lindholm B, Stenvinkel P. Cytokines, atherogenesis and hypercatabolism in chronic kidney disease: a dreadful triad. *Semin Dial.* 2009 Jul-Aug;22(4):381-6
255. Yamamoto T, Carrero JJ, Lindholm B, Stenvinkel P, Axelsson J. Leptin and urmic protein-energy wasting - The axis of eating. *Semin Dial.* 2009 Jul-Aug;22(4):387-9
256. Perna AF, Ingrosso D, Violetti E, Luciano G, Sepe I, Lanza D, Capasso R, Ascione E, Raiola I, Lombardi C, Stenvinkel P, Massy Z, de Santo NG. Hyperhomocysteinemia in uremia – a red flag in a disrupted circuit. *Semin Dial.* 2009 Jul-Aug;22(4):351-6
257. Massy ZA, Stenvinkel P, Drueke TB, The Role of Oxidative Stress in Chronic Kidney Disease. *Semin Dial.* 2009 Jul-Aug;22(4):405-8.
258. Yilmaz M, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P. The effect of renin angiotensin system blockade on pentraxin 3 levels in diabetic patients with proteinuria. *Clin J Am Soc Nephrol.* 2009 Mar;4(3):535-41
259. Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimbürger O, Hu M, Lin X, Stenvinkel P, Miller EJ. Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial dysfunction. *Mol Med.* 2009 Mar-Apr;15(3-4):70-5.
260. Chmielewski M, Carrero JJ, Qureshi AR, Axelsson J, Heimbürger O, Berglund L, Barany P, Rutkowski B, Lindholm B, Stenvinkel P. Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. *J Int Med* 2009 Jun;265(6):708-16.
261. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O, Barany P, Alvestrand A, Lindholm B, Suliman ME. High serum osteoprotegerin is associated with poor outcome especially in the presence of inflammation in chronic kidney disease. *J Nephrol.* 2009 Nov-Dec;22(6):774-82
262. Luttrupp K, Lindholm L, Carrero JJ, Griet Glorieux G, Vanholder R, Schalling M, Stenvinkel P, Nordfors L. Genetics/genomics in chronic kidney disease – towards personalized medicine? *Semin Dial.* 2009 Jul-Aug;22(4):417-22
263. Snaedal S, Olof Heimbürger O, Qureshi AR, Danielsson A, Wikström B, Fellström B, Fehrman-Ekholm I, Carrero JJ, Alvestrand A, Stenvinkel P, Bárány P. Comorbidity and acute

clinical events as determinants of CRP variation in hemodialysis patients: implications on patient survival. *Am J Kidney Dis.* 2009 Jun;53(6):1024-33.

264. Guo Q, Carrero JJ, Bárány P, Qureshi AR, Eriksson M, Anderstam B, Chmielewski M, Heimbürger O, Stenvinkel P, Lindholm B, Axelsson J. Associations of VEGF and its receptors sVEGFR-1 and 2 with protein-energy wasting, cardiovascular disease and survival in prevalent hemodialysis patients. *Nephrol Dial Transplant.* 2009 Nov;24(11):3468-73

265. Park S-H, Carrero JJ, Lindholm B, Stenvinkel P. Adiponectin in chronic kidney disease has opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. *Clin Nephrol* 2009; 72. 87-96

266. Carrero JJ, Hua X, Stenvinkel P, Qureshi AR, Heimbürger O, Barany P, Lindholm B, Frostegard J. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing hemodialysis. *Nephrol Dial Transplant.* 2009;24:3454-60.

267. Ekström T, Stenvinkel P. The epigenetic conductor - a genomic orchestrator in chronic kidney disease complications? *J Nephrol* 2009; 2009 Jul-Aug;22(4):442-9

268. Cordeiro AC, Carrero JJ, Abensur H, Lindholm B, Stenvinkel P. Systemic and local inflammation in peritoneal dialysis: mechanisms, biomarkers and effects of outcome. *Contrib Nephrol* 2009; 163:132-9

269. Vanholder R, Abou-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, De Deyn PP, Drüeke TB, Fliser D, Glorieux G, Herget-Rosenthal S, Hörl WH, Jankowski J, Jörres A, Massy ZA, Mischak H, Perna AF, Rodriguez-Portillo JM, Spasovski G, Stegmayr BG, Stenvinkel P, Thornalley PJ, Wanner C, Wiecek A. The role of EUTox in uremic toxin research. *Semin Dial* 2009 Jul-Aug;22(4):323-8

270. Vanholder R, Argilés A, Beige J, Brunet P, Drüeke TB, Fliser D, Herget-Rosenthal S, Hörl WH, Jörres A, Perna A, Rodriguez-Portillo M, Spasovski G, Stegmayr B, Stenvinkel P, Wanner C, Wiecek A, Massy ZA. Conservative treatment of the uremic syndrome. *Semin Dial.* 2009 Jul-Aug;22(4):449-53

271. Cordeiro A, Qureshi AR, Stenvinkel P, Heimbürger O, Axelsson J, Barany P, Lindholm B, Carrero JJ: Abdominal fat deposition is associated to increased inflammation, protein-energy wasting and worse outcome in patients undergoing hemodialysis. *Nephrol Dial Transplant.* 2010 Feb;25(2):562-8

272. Carrero JJ, Cordeiro A, Lindholm B, Stenvinkel P. The emerging pleiotropic role of adipokines in the uremic phenotype. *Curr Opin Nephrol Hypertens.* 2010 Jan;19(1):37-4

273. Carrero JJ, Stenvinkel P Can ghrelin improve appetite in uremic wasting? *Nat Rev Nephrol.* 2009 Dec;5(12):672-3

274. Carrero JJ, Witas A, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P, Suliman ME, Anderstam B, Lindholm B, Nordfors L, Schalling M, Axelsson J. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. *Nephrol Dial Transplant*. 2010;25(3):901-6.
275. Molanaei H, Carrero JJ, Heimbürger O, Nordfors L, Lindholm B, Stenvinkel P, Ingegerd Odar-Cederlöf I, Bertilsson L. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *Eur J Clin Pharmacol*. 2010 Mar;66(3):269-73.
276. Raj DS, Carrero JJ, Shah VO, Qureshi AR, Bárány P, Heimbürger O, Lindholm B, Ferguson J, Moseley PL, Stenvinkel P. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. *Am J Kidney Dis*. 2009 54(6):1072-80
277. Carrero JJ and Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal *Clin J Am Soc Nephrol*. 2009 Dec;4 Suppl 1:S49-55
278. Francisco ALM, Stenvinkel P, Valount S. Inflammation and its impact on anaemia in chronic kidney disease: from hameglobin variability to hyporesponsiveness. *NDT Plus* 2009; 2 [Suppl 1]: i18-i26
279. Chambers JC, Zhang E et al. genetic loci influencing kidney function and chronic kidney disease in man. *Nat Genet*. 2010 May;42(5):373-5
280. Olausson H, Qureshi AR, Miyamoto T, Barany P, heimbürger O, Lindholm B, Stenvinkel P, Larsson TE. Relation between serum fibroblast growth factor-12 level and mortality in incident dialysis patients: Are gender and cardiovascular disease confounding the relationship? *Nephrol Dial Transplant*. 2010 Sep;25(9):3033-8
281. Luksha N, Luksha L, Carrero JJ, Hammarqvist F, Stenvinkel P, Kublickiene K. Impaired resistance artery function in patients with end-stage renal disease. *Clin Sci (Lond)*. 2011 Jun;120(12):525-36.
282. Eckardt K-U, Kim, J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall. Hemoglobin variability is not an independent predictor of mortality in a European hemodialysis population. *J Am Soc Nephrol*. 2010 Oct;21(10):1765-75.
283. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease – what have we learned in 10 years? *Semin Dial*. 2010 Sep;23(5):498-509.
284. Meuwese CL, Halbesma N, Stenvinkel P, Dekker FW, Molanaei H, Qureshi AR, Peter Barany P, Heimbürger O, Lindholm B, Krediet RT, Boeschoten EW and Carrero JJ². Variations

in C-reactive protein during a single hemodialysis session do not associate with mortality. *Nephrol Dial Transplant*. 2010 Nov;25(11):3717-23

285.Korkeila M, Carrero JJ, Cederholm T, Stenvinkel P. Ghrelin – en ny möjlighet att behandla anorexi och undernäring vid kronisk katabol sjukdom. *Läkartidningen* 2010; 107:1627-28

286.Yamamoto T, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P, Axelsson J. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. *Nephrol Dial Transplant*. 2010 Dec;25(12):4017-23.

287.Sjögren P, Cederholm T, Heimbürger M, Stenvinkel P, Vedin I, Palmblad J, Hellenius ML. Simple advice on life-style habits and long-term changes in biomarkers of inflammation and vascular adhesion in healthy middle-aged men. *Eur J Clin Nutr*. 2010 Dec;64(12):1450-6.

288.Verduijn M, Prein RA, Stenvinkel P, Carrero JJ, le Cessie S, Witas A, Nordfors L, Krediet RT, Boeschoten EW, Dekker FW. Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. *Nephrol Dial Transplant*. 2011 Jan;26(1):239-45.

289.Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, Bárány P, Heimbürger O and Stenvinkel P. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. *Nephrol Dial Transplant*. 2011;26:184-90.

290.Stenvinkel P. Chronic kidney disease – a public health priority and harbinger of premature cardiovascular disease. *J Intern Med*. 2010;268:456-67

291.Witas A, Carrero JJ, Heimbürger O, Lindholm B, Hammarqvist F, Stenvinkel P, Nordfors L. Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in chronic kidney disease stage 5 patients. *J Intern Med*. 2011;269:410-9.

292.Anderwald C, Ankersmith HJ et al. Research update for articles published in EJCI 2008. *Eur J Clin Invest*. 2010 Sep;40(9):770-789

293.Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, Barany P, Heimbürger O, Lindholm B, Krediet RT, Boeschoten EW, Carrero JJ. Trimestral variation of C-reactive protein, interleukin-6 and tumour necrosis factor- α are similarly associated with survival in hemodialysis patients. *Nephrol Dial Transplant*. 2011 26:1313-8.

294.Miyamoto T, Qureshi AR, Yamamoto T, Lindholm B, Stenvinkel P, Alvestrand a, Axelsson J. Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2011 Jul;26(7):2231-7.

295.Muntinghe F, Carrero JJ, Navis, G, Stenvinkel P. TNFa levels are not increased in inflamed patients carrying the CCR5 deletion. *Cytokine*. 2011;53:16-8.

296. Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin and mortality in hemodialysis patients. *Kidney Int.* 2011 Apr;79(7):749-56.
297. Ehret GB, Munroe PB, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature.* 2011; 11;478(7367):103-9.
298. Wain LV, Verwoert GC, O'Reilly PF, Shi G, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet.* 2011 Sep 11;43(10):1005-11.
299. Witas A, Carrero JJ, Hammarqvist F, Qureshi AR, Heimbürger O, Schalling M, Lindholm B, Nordfors L and Stenvinkel P. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. *Eur J Clin Invest.* 2011 May;41(5):498-506.
300. Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B, Anderstam B. Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. *Clin Chim Acta.* 2010 Dec 14;411(23-24):2079-82.
301. Stenvinkel P. Adiponectin in chronic kidney disease: A complex and context sensitive clinical situation. *J Renal Nutr* 2011;21: 82-86
302. Baria F, Kamimura MA, Avesani CM, Lindholm B, Stenvinkel P, Draibe SA, Cuppari L. Activity-related energy expenditure of patients undergoing hemodialysis. *J Ren Nutr.* 2011 May;21(3):226-34.
303. Cordeiro AC, Carrero JJ, Barany P, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P. Influence of erythropoiesis-stimulating agents on glycosylated hemoglobin in non-diabetic kidney diseases starting dialysis. *Am J Nephrol* 2011;33:17-24
304. Axelsson J, Aström G, Sjölin E, Qureshi AR, Lorente-Cebrián S, Stenvinkel P, Rydén M. Uremic sera stimulate lipolysis in human adipocytes: role of perilipin. *Nephrol Dial Transpl Nephrol Dial Transplant.* 2011 Aug;26(8):2485-91.
305. Carrero JJ, Stenvinkel P. Predialysis chronic kidney disease in 2010: Novel targets for slowing CKD progression. *Nat Rev Nephrol.* 2011 Feb;7(2):65-6.
306. De Francisco ALM, Kim, J, Anker SD, Belzeroff V, Canaud B, Chazot C, Drueke TB, Eckardt KU, Floege J, Kronenberg F, MacDougall, Marcelli D, Molemans B, Passlick-Deetjen J, Schernthaner G, Stenvinkel P, Wheeler DC, Fouquerray B, Aljama P. An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: Results of the ARO study. *Nephron Clin Pract* 2011;118:c143-c154

307. Kalantar-Zadeh K, Cano N, Budde K, Chazot C, Kovesdy CP, Mak RH, Mehrotra, Raj DS, Sehgal AR, Stenvinkel P, Ikizler TA. Diets and Enteral Supplements for Improving Nutritional Status and Outcomes in Chronic Kidney Disease. *Nat Rev Nephrol.* 2011;7:369-84.
308. Miyamoto T, Carrero JJ, Qureshi AR, Anderstam A, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P. Circulating follistatin in patients with chronic kidney disease; implications for muscle strength, bone mineral density, inflammation and survival. *Clin J Am Soc Nephrol.* 2011 May;6(5):1001-8.
309. Chmielewski M, Verduijn M, Drechsler D, Lindholm B, Stenvinkel P, Rutkowski B, Boeschoten EW, Krediet RT, Dekker FW. Low cholesterol in dialysis patients – causal factor for mortality or an effect of confounding? *Nephrol Dial Transplant.* 2011;26:3325-31.
310. Meuwese C, Stenvinkel P, Dekker F, Carrero JJ. Regular monitoring of C-reactive protein in the dialysis patient: forewarned is forearmed. *Nature Reviews Nephrology* 2011;7, 166-176
311. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Cakar M, Altun B, Yenicesu M, Carrero JJ. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. *Nephrol Dial Transplant.* 2011 Nov;26(11):3537-43.
312. Stenvinkel P. Inflammation as a target for improving health in chronic kidney disease. *F1000 Med Rep.* 2010 Dec 17;2:88.
313. Akar H, Akar GC, Carrero JJ, Stenvinkel P, Lindholm B. Systemic consequences of poor oral health in chronic kidney disease patients. *Clin J Am Soc Nephrol.* 2011 Jan;6(1):218-26.
314. Meuwese C, Carrero JJ and Stenvinkel P. Recent insights in inflammation-associated wasting in patients with chronic kidney disease. *Contrib Nephrol* 2011;171:120-6.
315. Chmielewski M, Lindholm B, Stenvinkel P, Ekström TJ. The role of epigenetics in kidney diseases. *Prilozi.* 2011 Jul;32(1):45-54
316. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. *J Cachex Sarcopenia Muscle.* 2011 ;2(1):9-25.
317. Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P. Testosterone deficiency is a cause of anemia and reduced responsiveness to erythropoiesis stimulating agents in men with chronic kidney disease. *Nephrol Dial Transplant.* 2012 ;27(2):709-15.
318. Shearer G, Carrero JJ, Heimbürger O, Barany P, Stenvinkel P. Plasma fatty acids in chronic kidney disease: nervonic acid predicts mortality. *J Ren Nutr.* 2012 Mar;22(2):277-83.
319. Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, Eyileten T, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU, Yenicesu M, Carrero JJ.

- Endogenous Testosterone, Endothelial Dysfunction, and Cardiovascular Events in Men with Nondialysis Chronic Kidney Disease. *Clin J Am Soc Nephrol*. 2011 Jul;6(7):1617-25.
320. Breit SN, Carrero JJ, Tsai WW, Yagoutifam N, Luo W, Kuffner T et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end stage renal disease. *Nephrol Dial Transplant*. 2012 Jan;27(1):70-5.
321. Carrero JJ, Stenvinkel. Authors reply. *Kidney Int* 2011;80:783-784
322. Molanaei H, Stenvinkel P, Qureshi AR, Carrero JJ, Heimbürger O, Lindholm B, Diczfalusy U, Odar-Cederlöf I and Bertilsson L. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. *Eur J Clin Pharmacol*. 2012 May;68(5):571-7.
323. Ehret GB, Munroe et al. International Consortium for Blood Pressure Genome-Wide Association Studies, Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*. 2011;478:103-9.
324. Carrero JJ, Stenvinkel. Authors reply. *Kidney Int*. 2011 Oct;80(8):894.
3325. Park SH, Stenvinkel P, Lindholm B. Cardiovascular biomarkers in chronic kidney disease. *J Ren Nutr*. 2012 Jan;22(1):120-7.
326. Miyamoto T, Rashid Qureshi A, Heimbürger O, Bárány P, Carrero K, Sjöberg B, Lindholm B, Stenvinkel P, Carrero JJ. Inverse Relationship between the Inflammatory Marker Pentraxin-3, Fat Body Mass, and Abdominal Obesity in End-Stage Renal Disease. *Clin J Am Soc Nephrol*. 2011 Dec;6(12):2785-91.
327. Stenvinkel P, Bárány P. Dialysis in 2011: Can cardiovascular risk in dialysis patients be decreased? *Nat Rev Nephrol*. 2011 Dec 13;8(2):72-4.
328. Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, Saglam M, Stylianou K, Yaman H, Taslipinar A, Vural A, Gok M, Yenicesu M, Daphnis E, Yilmaz MI. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. *Clin J Am Soc Nephrol*. 2012 Feb;7(2):207-15.
329. Meuwese CL, Dekker FW, Lindholm B, Qureshi AR, Heimbürger O, Barany P, Stenvinkel P, Carrero JJ. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. *Clin J Am Soc Nephrol*. 2012;7(1):131-8.
330. Jia T, Carrero JJ, Lindholm B, Stenvinkel P. The complex role of adiponectin in chronic kidney disease. *Biochimie*. 2012 Oct;94(10):2150-6.
331. Nordfors L, Luttropp k, Carrero JJ, Witasp A, Stenvinkel P, Lindholm B, Schalling M. Genetic studies in chronic kidney disease: basic concepts. *J Nephrol*. 2012;25:141-9.

332. Stenvinkel P, Barany P. Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesis-stimulating agents. *Contrib Nephrol.* 2012;178:35-9.
333. Luksha L, Stenvinkel P, Folke Hammarqvist F, Carrero JJ, Davidge ST, Kublickiene K. Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. *PLoS One.* 2012;7(4):e36056.
334. Huang X, Stenvinkel P, Qureshi AR, Risérus U, Cederholm T, Bárány P, Heimbürger O, Lindholm B, Carrero JJ. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. *Nephrol Dial Transplant.* 2012 Sep;27(9):3615-20.
335. Stenvinkel P. Can treatment of persistent inflammation limit the extent of protein energy wasting in uremia? *Semin Dial.* 2013;26:16-9.
336. Gama-Axelsson T, Heimbürger O, Stenvinkel P, Barany B, Lindholm L, and Qureshi AR. Serum Albumin as Predictor of Nutritional Status in Patients with ESRD. *Clin J Am Soc Nephrol.* 2012 Sep;7(9):1446-53.
337. Xiaoyan H, Stenvinkel P, Qureshi A, Cederholm T, Barany P, Heimbürger O, Lindholm B, Riserus U, Carrero JJ. Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients. *J Intern Med.* 2013 Mar;273(3):263-72.
338. Gama-Axelsson T, Lindholm L, Heimbürger O, Stenvinkel P, Barany B, and Qureshi AR. Self-Rated Appetite as a Predictor of Mortality in Patients With Stage 5 Chronic Kidney Disease. *J Ren Nutr.* 2013 Mar;23(2):106-13.
339. Kato S, Lindholm B, Stenvinkel P, Ekström TJ, Luttrupp K, Yuzawa Y, Yasuda Y, Tsuruta Y, Maruyama S. DNA Hypermethylation and Inflammatory Markers in Incident Japanese Dialysis Patients. *Nephron Extra.* 2012; 2: 159–168.
340. Johnson RJ, Stenvinkel P, Martin SL, Jani A, Sanchez-Lozada LG, Hill JO, Lanaspa MA. Redefining Metabolic Syndrome as a Fat Storage Condition Based on Studies of Comparative Physiology. *Obesity (Silver Spring).* 2012 Sep 13. doi: 10.1002/oby.20026. [Epub ahead of print]
341. Cigarran S, Barril G, Aguliera, Coronel F. Stenvinkel P, Carrero JJ. Endogenous testosterone as a determinant of muscle strength and fat-free mass in non-dialyzed men with chronic kidney disease. *J Ren Nutr.* 2012 Oct 6. pii: S1051-2276
342. Park SH, Jia T, Qureshi AR, Barany P, Heimbürger O, Larsson TE, Axelsson J, Stenvinkel P, Lindholm B. Determinants and survival implications of low bone mineral density in end-stage renal disease patients. *J Nephrol.* 2012 Sep 13:0. doi: 10.5301/jn.5000185. [Epub ahead of print]

343. Carrero JJ, Stenvinkel P. The vulnerable uremic man – Impact of testosterone deficiency on the uremic phenotype. *Nephrol Dial Transpl* 2012;27(11):4030-41.
344. Heimbürger O, Stenvinkel P, Barany P. Creatinine The enigma of decreased creatinine generation in acute kidney injury. *Nephrol Dial Transplant*. 2012;27:3973-4.
345. Stenvinkel P, Jani A, Johnson R. Hibernating bears (ursidae) – metabolic magicians of definite interest for the nephrologist. *Kidney Int*. 2013;83:207-12.
346. Witasap A, Nordfors L, Carrero JJ, Luttrupp K, Lindholm B, Schalling M, Stenvinkel P. Genetic studies in chronic kidney disease: interpretation and clinical applicability. *J Nephrol*; 2012 Nov-Dec;25(6):851-64
347. Stenvinkel P, Larsson T. Chronic kidney disease – a model of premature aging. *Am J Kidney Dis*. 2013 Aug;62(2):339-51.
348. Anderstam B, Bragfors-Helin AC, Axelsson J, Qureshi AR, Wibom R, Lindholm B, Stenvinkel P. Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects. Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects. *Scand J Clin Lab Invest*. 2013 Mar;73(2):154-60.
349. Leurs P, Lindholm B, Stenvinkel P. Effects of hemodiafiltration on uremic inflammation. *Blood Purif*. 2013;35 Suppl 1:11-7.
350. Gracia-Iguacel C, Qureshi AR, Avesani CM, Heimbürger O, Huang X, Lindholm B, Bárány P, Ortiz A, Stenvinkel P, Carrero JJ. Subclinical versus overt obesity in dialysis patients; more than meets the eye. *Nephrol Dial Transplant*. 2013;28 Suppl 4:iv175-81.
351. Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. *Nature Genet*. 2012;44:904-9.
352. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. *J Am Soc Nephrol*. 2012;2:1258-70.
353. Carrero JJ, Stenvinkel P, Cuppari L et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). *J Renal Nutr* 2013;23:77-90
354. Leurs P, Lindholm B, Stenvinkel P. Effects of hemodiafiltration on uremic inflammation. *Blood Purif* 2013;35(Suppl 1); 11-17
355. Jia T, Qureshi AR, Brandenburg V, Ketteler M, Barany P, Heimbürger O, Uhlin F, Magnusson P, Fernström A, Lindholm B, Stenvinkel P, Larsson TE. Determinants of FGF23 and PTH variability in dialysis patients. *Am J Nephrol*. 2013;37(5):462-471.

356. Stenvinkel P, Ikizler TA and Carrero JJ. Obesity and Nephrology – Results of a knowledge and practice pattern survey. *Nephrol Dial Transplant*. 2013;28 Suppl 4:iv99-iv104.
357. Huang X, Lindholm B, Stenvinkel P, Carrero JJ. Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. *In Press J Nephrology* 2013
358. Witasp A, Ryden M, Carrero JJ, Qureshi AR, Nordfors L, Näslund E, Hammarqvist F, Arefin S, Kublickeine K, Stenvinkel P. Elevated circulating and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. *PlosONE* 2013; 8: e63493
359. Ghanavatian S, My Diep L, Bárány P, Heimbürger O, Seeberger A, Stenvinkel P, Rohani M, Agewall S. Subclinical Atherosclerosis, Endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. *Angiology*. 2013 Apr 7. [Epub ahead of print]
360. Xu H, Cabezas-Rodriguez I, Qureshi AR, Heimbürger O, Barany P, Anderstam B, Bragfors Helin AC, Carrero JJ, Stenvinkel P, Lindholm B. Increased levels of modified advanced oxidation protein products are associated with central and peripheral blood pressure in peritoneal dialysis patients. *Perit Dial Int*. 2014 Mar 1.
361. Ikizler, TA, Cano, NJ, French H, Fouque D, Himmelfarb J, Kalantar-ZAdeh K, Kuhlman MK, Stenvinkel P, ter Wee P, Teta D, Wang A Y-M, Wanner C. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. *Kidney Int*. 2013;84:1096-107.
362. Yuan J, Guo Q, Qureshi AR, Anderstam B, Eriksson M, Heimbürger O, Bárány P, Stenvinkel P, Lindholm B. Circulating vascular endothelial cell growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) is associated with inflammation and mortality in incident dialysis patients. *Nephrol Dial Transplant*. 2013;28:2356-63.
363. Cardozo LFMF, Pedruzzi LM, Stenvinkel P, Stockler-Pinto MB, Daleprane JB, Leite M, Mafra D. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. *Biochimie*. 2013;95(8):1525-33.
364. Bello AK, Stenvinkel P, Lin M, Hemmelgarn B, Thadhani R, Klarenbach S, Chan C, Zimmerman D, Cembrowski G, Strippoli G, Carrero JJ, Tonelli M. Serum testosterone levels and clinical outcomes in male hemodialysis patients. *Am J Kidney Dis*. 2013. doi:pii: S0272-6386(13)00985-2.
365. Yuan J, Watanabe M, Suliman M, Qureshi AR, Stenvinkel P, Lindholm B. Lindholm B. Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. *Nephrol Dial Transplant*. 2013 Aug 24.

366. Stenvinkel P. Vaskulär förkalkning: ett vanligt men förbisett tillstånd. *Läkartidningen* 2013;21:1041-44
367. Kalantar-Zadeh K, Rhee C, Sim JS, Stenvinkel P, Anker S, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. *J Cachexia Sarcopenia Muscle*. 2013;4(2):89-94.
368. Shiraki N, Nakashima A, Doi S, Carrero JJ, Sugiya N, Ueno T, Stenvinkel P, Kohno N, Masaki T. Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis. *Clin Exp Nephrol*. 2013 Jul 26. [Epub ahead of print]
367. Stenvinkel P. Okänd folksjukdom som drabbar allt fler. *Läkartidningen* 21;1015, 2013
368. Abete P, Adlbrecht C, Assimakopoulos SF, Côté N, Dullaart RP, Evsyukova HV, Fang TC, Goswami N, Hinghofer-Szalkay H, Ho YL, Hoebaus C, Hülsmann M, Indridason OS, Kholová I, Lin YH, Maniscalco M, Mathieu P, Mizukami H, Ndrepepa G, Roessler A, Sánchez-Ramón S, Santamaria F, Schernthaner GH, Scopa CD, Sharp KM, Skuladottir GV, Steichen O, Stenvinkel P, Tejera-Alhambra M, Testa G, Visseren FL, Westerink J, Witasp A, Yagihashi S, Ylä-Herttua S. Research update for articles published in EJCI in 2011. *Eur J Clin Invest*. 2013 Jul 3. doi: 10.1111
369. Bello AK, Stenvinkel P, Lin M, Hemmelgarn B, Thadhani R, Klarenbach S, Chan C, Zimmerman D, Cembrowski G, Strippoli G, Carrero JJ, Tonelli M. Serum testosterone levels and clinical outcomes in male hemodialysis patients. *Am J Kidney Dis*, In Press 2013
370. Frostegård AG, Hua X, Su J, Carrero JJ, Heimbürger O, Bárány P, Stenvinkel P, Frostegård J. IgM antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in hemodialysis patients, negatively associated with mortality. *Clin Exp Immunol*. 2013;174(3):441-8.
371. Meuwese CL, Carrero JJ, Cabezas-Rodríguez I, Heimbürger O, Barany P, Lindholm B, Qureshi AR, Ripsweden J, Dekker FW, Stenvinkel P. Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? *J Intern Med*. 2013 Jul 1.
372. Stenvinkel P, Zoccali C, Ikizler A. Obesity in chronic kidney disease - What should Nephrologists know? *J Am Soc Nephrol* 2013;24:1727-36
373. Stenvinkel P, Johnson R. *Kidney* Biomimicry – A rediscovered scientific field that could provide hope to patients with kidney disease. *Arch Med Res*. 2013;44:584-90.
374. Yuan J, Suliman M, Qureshi AR, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B. Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in

chronic kidney disease stage 5 patients with protein-energy wasting. *Nephrol Dial Transpl In Press* 2013

375. Stenvinkel P, Fröbert O, Anderstam B, Palm F, Eriksson M, Bragfors-Helin AC, Qureshi AR, Larsson T, Friebe A, Zedrosser A, Josefsson J, Svensson M, Sahdo B, Bankir L, Johnson RJ. Metabolic Changes in Summer Active and Anuric Hibernating Free-Ranging Brown Bears (*Ursus arctos*). *PLoS ONE* 2013 8(9): e72934.

376. Meuwese CL, Dekkers OM, Stenvinkel P, Dekker FW, Carrero JJ. Nonthyroidal illness and the cardiorenal syndrome. *Nature Rev Nephrol.* 2013;9:599-609

377. Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J. Vitamin K1 to Slow Vascular Calcification in Hemodialysis Patients (VitaVasK trial): Rationale and Study Protocol. *Nephrol Dial Transpl In Press* 2013

378. Jia T, Gama Axelsson T, Heimbürger O, Barany P, Lindholm B, Stenvinkel P, Qureshi AR. IGF-1 and Survival in ESRD. *Clin J Am Soc Nephrol.* 2014;9:120-7.

379. Abu Seman N, Witasp A, Wan Mohamad WN, Anderstam B, Brismar K, Stenvinkel P, Gu HF. Evaluation of the Association of Plasma Pentraxin 3 Levels with Type 2 Diabetes and Diabetic Nephropathy in a Malay Population. *J Diabetes Res.* 2013;2013:298019.

380. Huang X, Lindholm B, Stenvinkel P, Carrero JJ. Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. *J Nephrol.* 2013;26:960-74.

381. Alvarez-Aguilar C, Alvarez-Paredes AR, Lindholm B, Stenvinkel P, García-López E, Mejía-Rodríguez O, López-Meza JE, Amato D, Paniagua R. Effects of dopamine on leptin release and leptin gene (OB) expression in adipocytes from obese and hypertensive patients. *Int J Nephrol Renovasc Dis.* 2013;6:259-68.

382. Witasp A, Ekström TJ, Lindholm B, Stenvinkel P, Schalling M, Nordfors L. Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype. *Nephrol Dial Transplant.* 2014 Nov 13. [Epub ahead of print]

383. Saldanha, JF, de O Leal V, Stenvinkel P, Carraro-Eduardo JC, Mafra D. Resveratrol: Why is it a promising Therapy for Chronic Kidney Disease Patients? *Oxid Med Cell Longev.* 2013; 963217.

384. Witasp A, Carrero JJ, Michaelsson K, Ahlström H, Kullberg J, Adamsson V, Riserus, Larsson A, Helmersson-Karlqvist J, Lind L, Stenvinkel P, Ärnlöf J. The inflammatory marker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. *In Press Obesity* 2014

385. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, et al. Bardoxolone methyl in

- type 2 diabetes and stage 4 chronic kidney disease. *N Engl J Med*. 2013;369:2492-503.
386. Xu H, Huang X, Arnlöv J, Cederholm T, Stenvinkel P, Lindholm B, Risérus U, Carrero JJ. Clinical Correlates of Insulin Sensitivity and Its Association with Mortality among Men with CKD Stages 3 and 4. *Clin J Am Soc Nephrol*. 2014 Jan 16. [Epub ahead of print].
387. Bobrowski L, Łukaszuk T, Lindholm B, Stenvinkel P, Heimbürger O, et al. Selection of Genetic and Phenotypic Features Associated with Inflammatory Status of Patients on Dialysis Using Relaxed Linear Separability Method. *PLoS One*. 2014 Jan 28;9(1):e86630.
388. Jia T, Huang X, Qureshi AR, Xu H, Arnlöv J, Lindholm B, Cederholm T, Stenvinkel P, Risérus U, Carrero JJ. Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. *Kidney Int*. 2014 Aug;86(2):383-91.
389. Carrero JJ, Evans, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson S, Jernberg T. Warfarin Kidney Dysfunction, and 2 Outcomes Following Acute Myocardial Infarction 3 in Patients With Atrial Fibrillation. *JAMA*. 2014;311:919-928.
390. Xu H, Watanabe M, Qureshi AR, Heimbürger O, Barany P, Anderstam B, Eriksson M, Stenvinkel P, Lindholm B. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. *Perit Dial Int*. In Press 2014
391. Snaedal S, Qureshi AR, Carrero JJ, Heimbürger O, Stenvinkel P, Bárány P. Determinants of N-Terminal Pro-Brain Natriuretic Peptide Variation in Hemodialysis Patients and Prediction of Survival. *Blood Purif*. 2014 Apr 8;37(2):138-145.
392. Yilmaz MI, Solak Y, Saglam M, Cayci T, Acikel C, Unal HU, Eyileten T, Oguz Y, Sari S, Carrero JJ, Stenvinkel P, Covic A, Kanbay M. The Relationship between IL-10 Levels and Cardiovascular Events in Patients with CKD. *Clin J Am Soc Nephrol*. 2014 Jul;9(7):1207-16.
393. Jayanti A, Morris J, Stenvinkel P, Mitra S. Home hemodialysis: Beliefs, attitudes, and practice patterns. *Hemodial Int*. 2014 ;18: 767-776
394. Danielsson K, et al. Delta-He: a novel marker of inflammation predicting mortality and ESA response in dialysis patients. *Clin Kidney J* 2014
395. Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Barany P, Heimbürger O, **Stenvinkel P***, **Carrero JJ***. Low muscle strength rather than low muscle mass associates with mortality in incident dialysis patients. *Clin J Am Soc Nephrol* In Press 2014 ***shared senior authorship**
396. Sjöberg B et al. Three-month variation of plasma pentraxin 3 compared to C-reactive protein, albumin and homocysteine levels in hemodialysis patients. *Clin Kidney J*. In Press 2014
397. Arner P, Bäckdahl J, Hemmingsson P, Stenvinkel P, Näslund E, Thorell A, Andersson DP,

- Caidahl K, Rydén M. Regional variations in the relationship between arterial stiffness and adipocyte volume or number in obese subjects. *Int J Obes (Lond)*. 2014 Jul 8.
398. Stenvinkel P, Irving GF, Wegener S, Eyre S, Rippe B, Segelmark M, Barany P, Samuelsson O. Phosphate additives in food a potential public health risk. High phosphate levels can lead to cardiovascular disease. *Lakartidningen*. 2014 Jul 2-15;111(27-28):1176-9.
399. Isoyama, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimbürger O, Bárány P, Stenvinkel P, Lindholm B. Plasma S100A12 and soluble RAGE levels and mortality in chronic kidney disease stage 5 patients. *Nephrol Dial Transplant*. 2014 Jul 28. [Epub ahead of print]
400. Kooman JP, Kotanko P, Schols AMWJ, Shiels PG, Stenvinkel P, Chronic kidney disease and premature aging: when more leads to less. *Nature Rev Nephrol* 2014;10(12):732-742.
401. Stenvinkel P, Kindberg J, Fröbert O. Biomimetik – att efterlikna naturen för att förebygga sjukdom. In Press *Läkartidningen* 2015
402. Cobo G, Gallar P, Gama-Axelsson T, Di Gioia C, Qureshi AR, Camacho R, Vigil A, Heimbürger O, Ortega O, Rodriguez I, Herrero JC, Bárány P, Lindholm B, Stenvinkel P, Carrero JJ. Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients. *J Nephrol*. 2014 Dec 12. [Epub ahead of print]
403. Stenvinkel P. Obesity-a disease with many aetiologies disguised in the same oversized phenotype: has the overeating theory failed? *Nephrol Dial Transplant*. 2014 Oct 31. pii: gfu338.
404. Stenvinkel P. The importance of weighing yourself regularly. Dr. Fox and the weight curve *Läkartidningen*. 2014 Jun 17-Jul 1;111(25-26):1101.
405. Cordeiro AC, Amparo FC, Oliveira MA, Amodeo C, Smanio P, Pinto IM, Lindholm B, Stenvinkel P, Carrero JJ. Epicardial fat accumulation, cardiometabolic profile and cardiovascular events in patients with stages 3-5 chronic kidney disease. *J Intern Med*. 2015 Jan 5. doi: 10.1111/joim.12344. [Epub ahead of print]
406. Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel P, Anker S, Wheeler DC, de Francisco AL, Marcelli D, Froissart M, Floege J. High cardiovascular event rates within the first weeks of starting hemodialysis. In Press *Kidney Int* 2015
407. Carlsson A et al. Endostatin, cathepsin S and cathepsin L, and their association with inflammatory markers and mortality in patients undergoing hemodialysis. *Blood Purif* In Press
408. Naohito Isoyama, Anna Machowska, Abdul Rashid Qureshi, Tae Yamamoto, Björn Anderstam, Olof Heimbürger, Peter Barany, Peter Stenvinkel, Bengt Lindholm. Elevated circulating S100A12 associates with vascular disease and worse clinical outcome in peritoneal dialysis patients. In Press *PDI*.

409. Lanaspa, MA, Epperson LE, et al. Opposing activity changes in AMP deaminase and AMP-activated protein kinase in the hibernating ground squirrel. In Press PlosOne
410. Stenvinkel P, Carrero JJ, van Walden F, Ikizler TA, Nader G. Muscle wasting in end stage renal disease promulgates premature death: Established, emerging and potential novel treatment strategies. In Press Nephrol Dial Transpl 2015